funds/insti selling as mentioned by Daniel. and lots of unanswered questions with regards to the patents infringement - receivables, the disputed products spice and nagajo series' contribution to the overall revenue. What's next if the disputed products are top selling products - stop selling products and revenue plunge or pay royalties to Nichia to continue selling the products?

Quarter , Inventory , Revenue , Inventory to Revenue Ratio
Q3 2025 , 387 , 257 , 1.5
Q2 2025 , 617 , 244 , 2.5
Q1 2025 , 617 , 241 , 2.6
Q4 2024 , 610 , 264 , 2.3
Q3 2024 , 613 , 273 , 2.2
Q2 2024 , 600 , 266 , 2.3
Q1 2024 , 615 , 274 , 2.2
Q4 2023 , 579 , 310 , 1.9
Q3 2023 , 541 , 272 , 2.0
Q2 2023 , 500 , 220 , 2.3
Q1 2023 , 476 , 215 , 2.2
Q4 2022 , 446 , 247 , 1.8
Q3 2022 , 450 , 252 , 1.8
Q2 2022 , 380 , 242 , 1.6
Q1 2022 , 342 , 242 , 1.4
Q4 2021 , 306 , 258 , 1.2
Q3 2021 , 267 , 175 , 1.5
Q2 2021 , 232 , 209 , 1.1
Q1 2021 , 188 , 206 , 0.9
Q4 2020 , 180 , 210 , 0.9
Q3 2020 , 179 , 159 , 1.1
Q2 2020 , 174 , 89 , 1.9
Q1 2020 , 158 , 118 , 1.3
Q4 2019 , 152 , 150 , 1.0
Q3 2019 , 147 , 126 , 1.2
Q2 2019 , 144 , 115 , 1.2
Q1 2019 , 146 , 113 , 1.3